[177Lu]Lu-PSMA-617 in patients with PSMA-positive metastatic androgen pathway modulator-naive/sensitive prostate cancer (PSMAddition): a phase 3 randomised, controlled trial

Overview of attention for article published in The Lancet, August 2026

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (99th percentile)
High Attention Score compared to outputs of the same age and source (91st percentile)

Mentioned by

news: 12 news outlets
blogs: 2 blogs

twitter: 33 X users
bluesky: 2 Bluesky users

Readers on

mendeley: 4 Mendeley

So far, Altmetric has seen 2 Bluesky posts from 2 Bluesky users, with an upper bound of 1,082 followers.

Adding 177Lu-PSMA-617 to standard therapy soon after diagnosis cut the risk of metastatic prostate cancer progression or death by 28%. Whether it delays death from all causes is still unclear. doi.org/hcd3k2

[177Lu]Lu-PSMA-617 in patients with PSMA-positive metastatic androgen pathway modulator-naive/sensitive #ProstateCancer (PSMAddition): a phase 3 randomised, controlled trial. www.thelancet.com/journals/lan...

This page shows the most recent Bluesky posts that mention this research output. Click here to find out how to access more activity.